Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response.

Summary

An AI-screened peptide, SK56, directly blocks gasdermin D pores, delaying pyroptosis and curbing cytokine efflux. In murine LPS and CLP sepsis models, SK56 improved survival without altering IL-1β or GSDMD cleavage, and reduced mitochondrial damage and bystander activation in organoid and dendritic cell assays.

Key Findings

• SK56 blocks GSDMD-NT pores and inhibits pyroptosis and cytokine release in macrophages.
• SK56 improves survival in LPS-induced endotoxemia and CLP polymicrobial sepsis in mice.
• SK56 does not affect IL-1β or GSDMD cleavage, indicating pore-level action.
• In organoid and immune co-cultures, SK56 reduces dendritic cell activation and prevents widespread death of human alveolar organoids; it also mitigates mitochondrial damage.

Clinical Implications

Although preclinical, GSDMD pore blockade could inaugurate a therapeutic class targeting pyroptosis in sepsis and other hyperinflammatory states; next steps include safety, PK/PD, and translational studies.

Limitations

• Preclinical mouse models may not fully recapitulate human sepsis heterogeneity.
• Peptide delivery, stability, and immunogenicity require evaluation for clinical translation.

Future Directions

Define SK56 PK/PD, toxicity, and delivery; test efficacy in additional infection models; and explore combinations with antibiotics or immunomodulators.